KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organon (OGN) Total Liabilities (2022 - 2025)

Historic Total Liabilities for Organon (OGN) over the last 6 years, with Q3 2025 value amounting to $12.6 billion.

  • Organon's Total Liabilities rose 315.69% to $12.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $12.6 billion, marking a year-over-year increase of 315.69%. This contributed to the annual value of $12.6 billion for FY2024, which is 413.09% up from last year.
  • Organon's Total Liabilities amounted to $12.6 billion in Q3 2025, which was up 315.69% from $12.8 billion recorded in Q2 2025.
  • Organon's Total Liabilities' 5-year high stood at $13.0 billion during Q3 2021, with a 5-year trough of $4.9 billion in Q1 2021.
  • Its 5-year average for Total Liabilities is $11.8 billion, with a median of $12.0 billion in 2024.
  • Per our database at Business Quant, Organon's Total Liabilities skyrocketed by 16366.0% in 2021 and then plummeted by 1119.43% in 2022.
  • Quarter analysis of 5 years shows Organon's Total Liabilities stood at $12.2 billion in 2021, then dropped by 2.81% to $11.8 billion in 2022, then increased by 2.37% to $12.1 billion in 2023, then grew by 4.13% to $12.6 billion in 2024, then grew by 0.13% to $12.6 billion in 2025.
  • Its Total Liabilities was $12.6 billion in Q3 2025, compared to $12.8 billion in Q2 2025 and $12.6 billion in Q1 2025.